NEW YORK (TheStreet) -- Optimer Pharmaceuticals (OPTR) was spiking by 4.9% to $13.61 after the company received approval from the Food and Drug Administration for its Dificid anti-bacterial drug for the treatment of clostridium difficile-associated diarrhea in adults 18 years of age and older.
was rising 3% to $63.05 after saying Tuesday
was falling 2.6% to $34.10 as it announced the sale of 25 million ordinary shares by certain existing shareholders to
Deutsche Bank Securities
was rising 1.5% to $22.54 in premarket trading Tuesday as
The Financial Times
reported that the chipmaker was getting ready to unveil its vision for a new class of mobile computers that it hopes could take over from netbooks, as it moves to
defend its core PC market against the threat from tablets.
was rising 1.2% to $36 as the Bermuda-based offshore drilling contractor announced that it has been awarded a new contract by petroleum exploration and production company
in Thailand for the jack-up rig, West Leda. The contract is for nine-months and worth about $35 million. The contract may be extended by six months.
was rising 1% to $41.36 as
reported that the financial services company plans to expand its Asia markets division by hiring 150 people this year.
was trading sideways at $26.83 after saying Tuesday it will
in all regions except Japan, Hong Kong and South Korea by the end of the week.
Medical devices company
was flat at $7.04 as it recalled more than 29,000 of its iCross Coronary Imaging Catheters due to complaints about detachments of the catheter tip.
is expected by analysts to report first-quarter profit of $1.16 a share after the markets close Tuesday.
plans to introduce an online service called Call of Duty Elite this fall and charge a monthly subscription fee for it, the
Wall Street Journal
-- Written by Andrea Tse in New York.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Copyright 2011 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.